Jeg bliver lige nødt til at oprette endnu en BioPorto-tråd (beklager, det bliver dog ved denne ene), på jeres fine side, så jeg har et sted, hvor jeg kan vælte rundt og notere ting.
1. EPO skriver i dag til mig:
"I have been given the information that the mention of the grant will be published in the European Patent Bulletin 09/46 on 11.11.09, which is the date the decision to grant will become effective."
2. Nyt studie offentliggjort:
http://finance.yahoo.com/news/Study-Suggests-that-NGAL-prnews-3499643260.html?x=0&.v=1
1. EPO skriver i dag til mig:
"I have been given the information that the mention of the grant will be published in the European Patent Bulletin 09/46 on 11.11.09, which is the date the decision to grant will become effective."
2. Nyt studie offentliggjort:
http://finance.yahoo.com/news/Study-Suggests-that-NGAL-prnews-3499643260.html?x=0&.v=1
6/10 2009 13:19 Kim 0
20314 OK med mig 
1. Den information du har modtaget fra EPO, fortæller at det offentliggøres i European Patent Bulletin, som er deres officielle " årgan " udadtil. Selve patentudstedelsen går selvfølgelig i forvejen for dette, så vi må antage at allerseneste dato for BioPorto's modtagelse altså ER 11/11-09.
2. Ser ud til at det dennegang vedr. BioSite/Inverness, med henvisning til samme. Dog findes der STADIG ikke noget konkret om NGAL på deres side.
Kim
1. Den information du har modtaget fra EPO, fortæller at det offentliggøres i European Patent Bulletin, som er deres officielle " årgan " udadtil. Selve patentudstedelsen går selvfølgelig i forvejen for dette, så vi må antage at allerseneste dato for BioPorto's modtagelse altså ER 11/11-09.
2. Ser ud til at det dennegang vedr. BioSite/Inverness, med henvisning til samme. Dog findes der STADIG ikke noget konkret om NGAL på deres side.
Kim
6/10 2009 13:58 Kim 020316 Så er Abbott også på banen med NGAL. De annoncere at de har fået CE-mærkning på det.
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0783.htm
synes pludselig det vælter frem med nye NGAL-links.
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0783.htm
synes pludselig det vælter frem med nye NGAL-links.
6/10 2009 14:13 ndrs 020317 Jeg vil forsøge at skjule min evige optimisme overfor BioPorto og blot sige, at disse tre nyheder sammenlagt er SÆRDELES interessante - mon ikke vi skal et stort hop frem allerede i dag.
October 06 2009
Annoucement no. 26
EPO decides to issue BioPorto?s NGAL cutoff patent on November 11, 2009
On November 11, 2009, the European Patent Office (EPO) will publish its decision to issue BioPorto?s NGAL cutoff patent in the European Patent Bulletin 09/46. The decision is thereby final and immediately after translations will be submitted in all the countries of Europe. The patents will subsequently be issued in the individual countries.
The issuance of BioPorto?s NGAL cutoff patent, EP 1 831 699, is an important milestone for the company. Not only is the issuance the termination of the recent dispute about rights. It also enables the company to enforce the rights in case of infringement on BioPorto?s rights to measurement of NGAL as a marker for acute kidney injury.
Further information:
Christina Tønnesen, Investor Relations
Tel. 45 29 00 00, e-mail [email protected]
Annoucement no. 26
EPO decides to issue BioPorto?s NGAL cutoff patent on November 11, 2009
On November 11, 2009, the European Patent Office (EPO) will publish its decision to issue BioPorto?s NGAL cutoff patent in the European Patent Bulletin 09/46. The decision is thereby final and immediately after translations will be submitted in all the countries of Europe. The patents will subsequently be issued in the individual countries.
The issuance of BioPorto?s NGAL cutoff patent, EP 1 831 699, is an important milestone for the company. Not only is the issuance the termination of the recent dispute about rights. It also enables the company to enforce the rights in case of infringement on BioPorto?s rights to measurement of NGAL as a marker for acute kidney injury.
Further information:
Christina Tønnesen, Investor Relations
Tel. 45 29 00 00, e-mail [email protected]
